“Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trial.”, Lancet Infect Dis, vol. 20, no. 9, pp. 1061-1070, 2020.
, “A vaccine-induced gene expression signature correlates with protection against SIV and HIV in multiple trials.”, Sci Transl Med, vol. 11, no. 507, 2019.
, ,
“Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humans.”, J Infect Dis, vol. 211, no. 4, pp. 518-28, 2015.
, “First-in-human evaluation of a hexon chimeric adenovirus vector expressing HIV-1 Env (IPCAVD 002).”, J Infect Dis, vol. 210, no. 7, pp. 1052-61, 2014.
, “First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001).”, J Infect Dis, vol. 207, no. 2, pp. 240-7, 2013.
, “Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys.”, Nature, vol. 482, no. 7383, pp. 89-93, 2012.
,